|
WO2020221380A1
|
|
Selective ligands of human constitutive androstane receptor
|
|
EP3757098A1
|
|
Cyclen based compounds, coordination compounds, peptides, pharmaceutical preparation, and use thereof
|
|
EP3747852A1
|
|
Compounds for chromatographic separation of rare earth elements and s-, p-, d- metals, method of separation, and use thereof
|
|
CZ2019216A3
|
|
3ą5ß-Neuroactive steroids for treating epilepsy and seizure disorders
|
|
IL265073D0
|
|
Catheter tube
|
|
EP3716957A1
|
|
Steroidal compounds for treatment of mental and neurological disorders
|
|
GB201811669D0
|
|
Method of production of particles
|
|
EP3545962A1
|
|
Nanodiamonds as artificial proteins for regulation of a cell signalling system
|
|
CZ2018121A3
|
|
Pyridinopyrrolopyrimidine ribonucleosides for therapeutic use
|
|
EP3492460A1
|
|
Compounds for separation of rare earth elements, method of separation, and use thereof
|
|
US2019161452A1
|
|
Process for the preparation of azidoperfluoroalkanes and N-polyfluoroalkyl azides
|
|
GB201709317D0
|
|
Inhibitors of Rhomboid Intramembrane Proteases
|
|
GB201709095D0
|
|
Mixed dimensional Heterostructure Films
|
|
CZ2017293A3
|
|
Polysubstituted pyrimidines
|
|
WO2018133887A1
|
|
Synthetic antimicrobial peptides and their applications for the treatment and prevention of musculoskeletal infections
|
|
CZ2016465A3
|
|
Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides for therapeutic use
|
|
US2019144487A1
|
|
Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
|
|
CZ2016342A3
|
|
15β-substituted estrone derivatives as selective inhibitors of 17β-hydroxysteoid dehydrogenases
|
|
CZ2016243A3
|
|
Second generation lipophosphonoxins and their use
|
|
CZ2016152A3
|
|
Transporter of nucleoside triphosphates across cell membrane, preparing and using it
|
